Throat Cancer: Types, Causes, Symptoms, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Throat cancer broadly encompasses malignancies arising from the larynx (voice box), oropharynx (back of the throat, tonsils, soft palate, base of tongue), and hypopharynx (the area surrounding and below the larynx). Squamous cell carcinoma (SCC) accounts for over 95% of cases. These cancers are traditionally linked to tobacco and alcohol use, though HPV (human papillomavirus) — particularly HPV-16 — now drives a rapidly rising proportion of oropharyngeal cancers in Western countries among younger non-smoking patients. Laryngeal cancer (glottic, supraglottic, subglottic) affects approximately 13,000 Americans annually and is strongly associated with tobacco use and alcohol. Oropharyngeal SCC incidence has doubled over the past two decades in developed countries largely due to HPV-related disease. HPV-positive oropharyngeal cancers have a markedly better prognosis than HPV-negative, tobacco-driven cancers, and de-escalation trials are investigating whether standard-intensity treatment can be safely reduced without compromising outcomes. Throat cancers collectively represent a significant cause of cancer-related morbidity — treatment may affect voice, swallowing, and breathing, requiring multidisciplinary rehabilitation.

Tobacco smoking is the dominant risk factor for laryngeal, hypopharyngeal, and HPV-negative oropharyngeal cancers. The relative risk for smokers is 10–15 fold compared to non-smokers, and the combination of tobacco and heavy alcohol consumption (>4 drinks/day) has a synergistic multiplicative effect. The mechanism involves direct carcinogen exposure — aromatic amines, polycyclic aromatic hydrocarbons, and nitrosamines in tobacco smoke causing TP53 and other tumor suppressor gene mutations. Alcohol acts as a co-carcinogen by increasing mucosal permeability to carcinogens, inducing oxidative stress, and suppressing DNA repair. HPV-16 infection causes a distinct molecular pathway of carcinogenesis in oropharyngeal cancer — the E6 and E7 oncoproteins inactivate p53 and pRb tumor suppressors. Transmission is through sexual (oral) contact; multiple oral sexual partners increase risk. Laryngeal papillomatosis (recurrent respiratory papillomatosis, caused by HPV-6 and HPV-11) rarely undergoes malignant transformation. Additional risk factors include poor oral hygiene, Plummer-Vinson syndrome, prolonged GERD (for subglottic/hypopharyngeal disease), occupational exposure to asbestos and strong acids, and immunosuppression.

Symptoms vary by tumor location. Laryngeal cancer (glottic — affecting the true vocal cords): early hoarseness is the cardinal symptom, often present when the tumor is still small and localized, enabling early diagnosis when hoarseness is investigated promptly. Supraglottic and hypopharyngeal cancers typically present late with dysphagia, odynophagia (painful swallowing), a foreign body sensation, referred otalgia (ear pain), and a neck mass — they are asymptomatic until locally advanced because there are no early cardinal symptoms. Oropharyngeal cancer presents with persistent sore throat, dysphagia, odynophagia, voice change ('hot potato' muffled voice), otalgia, and — most commonly as the first presentation — a painless or tender neck mass (lymph node metastasis). Hemoptysis (coughing blood), stridor (high-pitched breathing noise from airway narrowing), and dyspnea indicate advanced disease. Unintentional weight loss, difficulty opening the mouth (trismus), and decreased tongue mobility occur in locally advanced or infiltrative tumors. Any hoarseness persisting for more than 3 weeks in an adult — particularly a smoker or heavy drinker — mandates laryngoscopy.

Flexible nasolaryngoscopy performed in the outpatient clinic allows direct visualization of the larynx, base of tongue, piriform sinuses, and oropharynx, and identifies mucosal lesions for targeted biopsy. Rigid direct laryngoscopy and pan-endoscopy under general anesthesia permits comprehensive examination and multiple biopsies. Histopathology confirms SCC; p16 immunohistochemistry is mandatory for oropharyngeal cancer to determine HPV status. AJCC 8th edition staging separates HPV-positive and HPV-negative oropharyngeal SCC with distinct staging criteria. MRI of the head and neck with gadolinium contrast provides superior soft tissue delineation — cartilage invasion, base of tongue extension, perineural spread, and retropharyngeal node involvement are best assessed with MRI. CT with contrast characterizes cortical bone involvement and nodal staging. PET-CT is standard for staging and post-treatment response assessment, and detects synchronous primaries or distant metastases. Endoscopic ultrasound-guided FNA or core biopsy of suspicious neck nodes provides tissue confirmation. Hearing, speech-language pathology, and nutritional assessment are performed pre-treatment to guide supportive care and establish baseline functional status.

Treatment is highly multidisciplinary and individualized. For early glottic laryngeal cancer (T1–T2 N0): transoral laser microsurgery (TLM) with CO2 laser offers excellent local control (>90%) and voice preservation equivalent to radiotherapy, with a single-fraction or short-course treatment. Definitive radiotherapy (66–70 Gy in conventional fractionation) is an equally curative organ-preserving alternative. For locally advanced laryngeal and hypopharyngeal cancer (T3–T4 or N+): larynx-preservation approach (concurrent cisplatin-based chemoradiation — the EORTC 24891 and RTOG 91-11 paradigm) is preferred to avoid total laryngectomy in eligible patients. Total laryngectomy with voice prosthesis is performed for T4a disease with cartilage destruction or when chemoradiation fails. For oropharyngeal cancer: transoral robotic surgery (TORS) ± adjuvant radiotherapy or chemoradiation is now a standard organ-preserving surgical option for T1–T2 HPV-positive oropharyngeal cancers at experienced centers. Definitive concurrent cisplatin + IMRT (70 Gy) remains the gold standard for locally advanced oropharyngeal SCC. HPV-positive patients with N1–N2 disease have excellent prognosis (>85% 5-year OS) and are the focus of PATHOS, OPTIMA, and De-ESCALaTE de-escalation trials exploring reduced-intensity radiotherapy or chemotherapy. For recurrent/metastatic disease: pembrolizumab monotherapy (PD-L1 CPS ≥1) or pembrolizumab + platinum-fluoropyrimidine chemotherapy is first-line per KEYNOTE-048 trial evidence.

Throat cancer prognosis varies considerably by anatomical subsite, HPV status, and stage at diagnosis. Early glottic laryngeal cancer (T1 N0 M0) has one of the most favorable prognoses of any head and neck cancer, with cure rates exceeding 90% using either transoral laser microsurgery or definitive radiotherapy, and excellent preservation of natural voice quality. HPV-positive oropharyngeal cancer has undergone a paradigm shift in prognosis over the past two decades — 5-year overall survival exceeds 85% for most HPV-positive patients with N1–N2 disease treated with standard cisplatin-based chemoradiation, prompting multiple de-escalation trials (PATHOS, OPTIMA, De-ESCALaTE, HN002) to determine whether treatment intensity can be safely reduced without compromising outcomes. HPV-negative oropharyngeal cancer and supraglottic laryngeal cancer have 5-year overall survival rates of approximately 50–65% for locally advanced disease. Hypopharyngeal cancer, which typically presents late at locally advanced stage, has a 5-year overall survival of only 25–40% despite aggressive chemoradiation. Larynx preservation is achieved in 60–70% of patients with locally advanced laryngeal cancer treated with concurrent cisplatin-based chemoradiation protocols; total laryngectomy with voice prosthesis provides excellent functional voice restoration when required. Recurrent or metastatic throat cancer is treated with pembrolizumab ± chemotherapy (KEYNOTE-048), with median overall survival of approximately 13–14 months for PD-L1 CPS ≥1 tumors. Long-term functional impact on voice quality, swallowing, saliva production, and overall quality of life requires ongoing multidisciplinary rehabilitation including speech pathology, dietetics, and physiotherapy.

Tobacco cessation is the single most effective preventive measure for laryngeal and HPV-negative throat cancer — the risk of laryngeal cancer decreases significantly after smoking cessation and approaches non-smoker risk after 20 years of abstinence. Alcohol reduction substantially decreases risk, with a synergistic benefit when combined with tobacco cessation. HPV vaccination (Gardasil 9) against high-risk HPV-16 and HPV-18 is the most impactful preventive strategy for HPV-related oropharyngeal cancer — vaccination before sexual debut provides the highest protection and is recommended up to age 26 routinely. Vaccination up to age 45 may be considered after shared decision-making. While there is no established population screening for throat cancer, primary care clinicians should encourage annual oral cavity and oropharyngeal inspection in high-risk patients (smokers, heavy drinkers). Persistent hoarseness, dysphagia, or sore throat beyond 3 weeks in a smoker should be evaluated without delay. GERD management reduces chronic hypopharyngeal mucosal irritation.

Hoarseness (change in voice quality) persisting for more than 3 weeks in an adult, especially a current or former smoker, requires urgent referral for nasolaryngoscopy to exclude glottic carcinoma — early glottic cancer is highly curable when detected at T1 stage. A painless neck mass persisting for more than 2–3 weeks in an adult requires urgent head and neck specialist evaluation — it may represent a nodal metastasis from oropharyngeal or other pharyngeal primary. Progressive difficulty swallowing, odynophagia, or a constant sensation of something stuck in the throat lasting more than 3 weeks warrants ENT evaluation. Persistent unilateral earache (otalgia) without otological explanation — particularly with a sore throat — is referred ear pain from a pharyngeal or laryngeal primary and should not be dismissed. Stridor (noisy, high-pitched breathing) from laryngeal obstruction is a respiratory emergency. Any oral, oropharyngeal, or laryngeal mucosal ulcer or exophytic lesion that does not heal within 3 weeks requires biopsy. Patients with risk factors (smoking history, alcohol, multiple sexual partners) and new persistent throat or voice symptoms should seek medical evaluation without delay.